Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with...

Descripción completa

Detalles Bibliográficos
Autores: Vigón, Lorena, Vázquez-Morón, Sonia|||0000-0002-0977-741X, Berenguer, Juan|||0000-0001-8541-8200, González-García, Juan|||0000-0002-3652-002X, Jiménez-Sousa, Ma Ángeles, Guardiola Tey, Jose Maria|||0000-0001-5537-2600, Crespo Casal, Manuel|||0000-0001-9016-0515, de los Santos Gil, Ignacio|||0000-0001-7073-5211, Von Wichmann, Miguel Ángel, Carrero, Ana, Yélamos, María Belén, Gómez, Julián, Resino, Salvador|||0000-0001-8783-0450, Martínez, Isidoro|||0000-0002-9949-9264, Miralles, Pilar, López, J.C., Parras, F., Padilla Ortega, Belén, Aldámiz-Echevarría, T., Tejerina, F., Diez, Cristina, Pérez-Latorre, L., Fanciulli, Chiara|||0000-0003-2175-9027, Gutiérrez, I., Ramírez, Manuel|||0000-0003-0332-6973, Carretero, S., Bellón, José-María|||0000-0002-8492-1565, Bermejo, Javier|||0000-0002-5241-2758, Hontañón, V., Arribas, Jose|||0000-0002-7410-9450, Montes, M.L., Bernardino, I., Pascual, J.F., Zamora, Francisco, Peña, J.M., Arnalich, F., Díaz, M., Domingo Pedrol, Pedro|||0000-0003-1138-5770, Sanz, Jaime|||0000-0001-6934-4619, Bustinduy, M.J., Iribarren, José Antonio, Rodríguez-Arrondo, F., Eynde, E.Van den, Pérez, M., Ribera, E., Casado, José Luis|||0000-0002-7639-8591, Dronda, Fernando|||0000-0002-0443-5816, Moreno, A., Pérez Elías, Mª Jesus|||0000-0001-5700-5257, Sanfrutos, M.A., Moreno, S., Quereda, Carmen, Arranz, A., Casas Díaz, Encarna|||0000-0002-5901-6555, Miguel, J.de, Schroeder, S., Vergas, J., Téllez, M.J., Vinuesa, D., Muñoz, Lourdes, Hernández Quero, José, Ferrer, A., Galindo, María José, Ortiz, L., Ortega, Emilio|||0000-0002-2217-8905, Montero, M., Blanes, M., Cuellar, S., Lacruz, José, Salavert, Miguel|||0000-0002-8571-2124, López-Aldeguer, J., Pérez González, Gustavo|||0000-0001-9112-9042, Gaspar, G., Yllescas, M., Crespo, P., Aznar, E., Esteban, H.
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:286570
Acceso en línea:https://ddd.uab.cat/record/286570
https://dx.doi.org/urn:doi:10.1038/s41598-019-48592-5
Access Level:acceso abierto
Palabra clave:Antibodies
Hepatitis C
Hepatitis C virus
Descripción
Sumario:The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.

Similares en LA Referencia